EP3097094A1 - Fluor-naphthyl-derivate - Google Patents

Fluor-naphthyl-derivate

Info

Publication number
EP3097094A1
EP3097094A1 EP15702398.7A EP15702398A EP3097094A1 EP 3097094 A1 EP3097094 A1 EP 3097094A1 EP 15702398 A EP15702398 A EP 15702398A EP 3097094 A1 EP3097094 A1 EP 3097094A1
Authority
EP
European Patent Office
Prior art keywords
fluoro
methyl
naphthamide
compound
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15702398.7A
Other languages
English (en)
French (fr)
Other versions
EP3097094B1 (de
Inventor
Katrin Groebke Zbinden
Emmanuel Pinard
Thomas Ryckmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP15702398.7A priority Critical patent/EP3097094B1/de
Publication of EP3097094A1 publication Critical patent/EP3097094A1/de
Application granted granted Critical
Publication of EP3097094B1 publication Critical patent/EP3097094B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • R 1 is C 4 _6-cycloalkyl or C 4 _6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl;
  • A is phenyl, pyridinyl or piperidinyl
  • R is hydrogen, halogen, lower alkyl, cyano, C 4 _6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five-or six-membered heteroaryl group, optionally substituted by lower alkyl; n is 1 or 2;
  • WO 2011149801 describes similar compounds for treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.
  • the activity (EC 50 in nM) is about 2 or more times lower, and therefore these compounds are less suitable for the development of corresponding drugs.
  • the F- substitution on the naphthyl ring instead of OR 1 in WO 2011149801 leads to more active compounds, which could not predicted.
  • the compounds of the present invention are muscarinic Ml receptor positive allosteric modulators (PAM) and hence are useful in the treatment of diseases, mediated by the muscarinic Ml receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia,
  • PAM muscarinic Ml receptor positive allosteric modulators
  • Acetylcholine is a neurotransmitter which activates both nicotinic (ligand-gated ion channel) and muscarinic (metabotropic) receptors in the CNS and in the periphery.
  • the muscarinic receptors are members of the class A G-protein-coupled receptors. To date, five distinct subtypes of mAChRs (M1-M5) have been cloned and sequenced. The muscarinic Ml receptors are predominantly distributed in the brain, with the highest expression in the cortex, thalamus, striatum and hippocampus. In clinical studies, Xanomeline, a Ml/M4-preferring agonist, demonstrated robust efficacy on positive, negative and cognitive symptoms in schizophrenic patients and improved cognitive scores and reduced psychotic-like behaviors in patients with Alzheimer's disease (AD). The Ml receptor has been implicated in memory and learning processes, regulation of dopamine and NMD A receptor activity and has thus been proposed as a potential target for the treatment of AD and schizophrenia.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • Pathologically AD is characterized by the deposition in the brain of amyloid in extracellular plaques and intracellular neurofibrillary tangles.
  • the amyloid plaques are mainly composed of amyloid peptides (Abeta peptides) which originate from the ⁇ -Amyloid Precursor Protein (APP) by a series of proteolytic cleavage steps.
  • APP ⁇ -Amyloid Precursor Protein
  • the Abeta peptides are derived from the same domain of the APP but differ at their N- and C-termini, the main species are of 40 and 42 amino-acid length by processing of the beta-amyloid precursor protein (APP) by the beta- amyloid protein cleaving enzyme. The processing leads to accumulation of Abeta in the brain.
  • APP beta-amyloid precursor protein
  • Ml receptors are abundantly expressed postsynaptically in cortex, hippocampus and striatum which are important brain regions involved for cognition. Based on the cholinergic hypothesis i.e. degeneration of presynaptic cholinergic nerve terminals in hippocampus and cortical regions, Ml activation should rescue the cognitive deficits which occur in AD, thus providing symptomatic treatment of this neurodegenerative disorder. Postmortem studies in AD cortical tissues have shown that Ml receptor expression are not reduced, thus providing evidence for target availability in a critical brain region.
  • Ml activation has potential as a disease-modifying therapy for AD by shifting the APP processing towards the non-amyloidogenic a-secretase pathway and by decreasing tau hyperphosphorylation. Therefore, Ml PAMs provide an approach to target both symptomatic and disease-modifying treatment of AD.
  • Schizophrenia is a severe, disabling, lifelong disorder that affects 1% of the population and is characterized by positive symptoms (such as hallucinations, delusions and paranoia), negative symptoms (such as social withdrawal and apathy) and cognitive impairment (for example, deficits in working memory, executive function and attention). Schizophrenia is a neurodevelopmental disorder with genetic risk factors and neuropathological changes.
  • NMDA receptor function in pyramidal neurons coupled with sub-optimal dopamine release in critical regions such as dorsolateral prefrontal cortex may account for some of the cognitive deficits.
  • Ml receptors are located in regions which are affected in schizophrenia, such as the hippocampus, cortex and striatum, in particular in the medium spiny neurons.
  • Several reports have shown a reduction in muscarinic receptors in the prefrontal cortex and hippocampus, regions where Ml is densely expressed, in a subset of schizophrenic patients.
  • preclinical studies have shown that Ml knockout mice have enhanced amphetamine-induced activity and increased striatal dopamine levels. Electrophysiology studies have revealed that activation of Ml receptors potentiates NMDA mediated hippocampal activity, modulates activity of medium spiny neurons and increases activity of medial prefrontal cortex neurons. Overall, activation of Ml receptors should modulate dysfunctional dopaminergic and glutamatergic signaling within the underlying neurocircuitry resulting in improvements in the symptoms of schizophrenia.
  • an alternative approach consists of developing Ml PAMs that act at the less highly conserved allosteric binding sites.
  • M I PAMs from different chemical classes exhibiting, as rationalized, a good level of M I subtype selectivity.
  • these M 1 allosteric agents demonstrated pro-cognitive effects (in scopolamine-induced memory deficit in mice, scopolamine impaired non-human primates and in transgenic AD mice).
  • PQCA and ML 169 have been shown to promote non-am y I oidogen ic APP processing.
  • Electrophysiology studies have shown that Ml PAMs potentiate carbachol-induced activity in the medial prefrontal corte and medium spiny neurons.
  • M 1 PAMs do not appear to produce side effects such as salivation at therapeutic effective doses. Additionally, they are expected to be devoid of liabilities such as receptor
  • the PA M approach by activating in a truly selective manner M 1 receptors, is a highly promising novel strategy to deliver both efficacious and safe therapeutic agents for the treatment of schizophrenia (positive, negative and cognitive symptoms) as well as AD (symptomatic and disease modifyin ).
  • the compounds of the invention which are muscarinic Ml receptor positive allosteric modulators, are believed to be useful in the treatment of Alzheimer's disease and other diseases mediated by the muscarinic Ml receptor, without side effects.
  • the object of the present invention was to identify compounds that are muscarinic Ml receptor positive allosteric modulators. It has been found that the compounds of formula I are active in this area and they may therefore be used for the treatment of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders
  • the present invention relates to compounds of formula I and to their pharmaceutically acceptable salts, to these compounds as pharmaceutically active substances, to the processes for their production, as well as to the use in the treatment or prevention of disorders, relating to muscarinic Ml receptor positive allosteric modulators, and to pharmaceutical compositions containing the compounds of formula I.
  • the following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
  • lower alkyl denotes a saturated, i.e. aliphatic hydrocarbon group including a straight or branched carbon chain with 1 - 7 carbon atoms.
  • alkyl examples are methyl, ethyl, n-propyl, isopropyl, n- butyl, i-butyl, 2-butyl, t-butyl and the like.
  • C 4 _6-cycloalkyl denotes a saturated carbon ring, containing from 4 to 6 carbon ring atoms, for example cyclobutyl, cyclopentyl or cyclohexyl.
  • alkoxy denotes a group -O-R' wherein R' is lower alkyl as defined above.
  • halogen denotes chlorine, bromine, fluorine or iodine.
  • lower alkoxy substituted by halogen denotes an alkyl group as defined above, wherein at least one hydrogen atoms is replaced by halogen, for example OCF 3 , OCH 2 F, OCH 2 CF3, OCH 2 CH 2 CF3, OCH 2 CF 2 CF3 and the like.
  • C 4 _6-heterocycloalkyl denotes a non aromatic heterocyclic ring with 4 to 6 ring atoms, containing at least one O atom, for example tetrahydropyran-4-yl, tetrahydropyran-3-yl, oxolan-3-yl, oxetan-3-yl, oxetan-2-yl or tetrahydrofuran-2-yl.
  • five or six-membered heteroaryl denotes aromatic rings with 5 or 6 ring atoms, containing at least one N, S or O atom, for example pyrazolyl, imidazolyl, 1,2,4- triazolyl, thiazolyl, 1,2,4-oxadiazolyl or pyridinyl.
  • pharmaceutically acceptable salt or “pharmaceutically acceptable acid addition salt” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane- sulfonic acid, p-toluenesulfonic acid and the like
  • One embodiment of the present invention are compounds of formula I, wherein A is phenyl and the other substituents are as described above, for example the following compounds:
  • One further embodiment of the present invention are compounds of formula I, wherein A is pyridinyl and the other substituents are as described above, for example the following compounds:
  • One embodiment of the invention are further compounds of formula I, wherein A is piperidinyl and the other substituents are as described above, for example the following compound
  • an activating agent such as BOP (Benzotriazol-1- yloxy)tris(dimethylamino)phosphonium hexafluorophosphate or thionyl chloride to a compound of formula
  • the compounds of formula I may be prepared in accordance with process variant a) and with the following schemes 1 and 2.
  • Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto.
  • R 1 is as described above and R 2 is lower alkyl, C4_6-cycloalkyl or is a five-or six- membered heteroaryl group, optionally substituted by lower alkyl; Scheme 2
  • a compound of general formula la can be obtained by coupling acid V with an amine H 2 N-R1 (step 5). Alternatively, it can be obtained by reaction an amine H 2 N-R1 with acid chloride V (step 7).
  • a compound of general formula lb is obtained from a compound of general formula la by Suzuki reaction with a heteroaryl boronic acid or heteroaryl boronic acid ester or alternatively by reaction with dimethyl zinc or cyclopropyl boronic acid in the presence of a Pd catalyst (step 8).
  • a compound of general formula Ic is obtained by Suzuki reaction of a benzyl halogenide with a boronic acid ester of general formula VIII (step 11).
  • a compound of general formula Id is obtained by reductive amination of an aldehyde X with a substituted piperidine (step 14).
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures.
  • suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used.
  • the compounds of formula I are basic and may be converted to a corresponding acid addition salt.
  • the conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • an appropriate acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid,
  • the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent.
  • an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like.
  • the temperature is maintained between 0 °C and 50 °C.
  • the resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
  • the acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention have an activity as neurogenic agents.
  • the assay is designed to select compounds that possess modulator activity at the
  • acetylcholine muscarinic receptor expressed in CHO cells by measuring the intracellular calcium with a Fluorometric Imaging Plate Reader System (FLIPR, Molecular Devices).
  • FLIPR Fluorometric Imaging Plate Reader System
  • the assay study the effect of several concentrations of test compounds on basal or acetylcholine - stimulated Ca 2+ levels using FLIPR.
  • BioCoat 96 well black/clear plate (Becton 35 4640). The cells are grown at 37°C and 5% C0 2 in the following medium: F12 Nut Mix (Gibco 21765), 10% FCS heat inactivated (GIBCO 16000-044), 1 % Pen Strep (Gibco,15140) and 200 ⁇ g/ ml Geneticin (Gibco 11811).
  • Two minutes preincubation with the diluted test compounds is provide to determine any agonist activity on the Ml receptor by comparison to 30 nM Acetylcholine control.
  • the diluted compounds were added to cells and after two minutes preincubation, the EC 2 o of acetylcholine is added followed by another two minutes preincubation before the
  • the 26 compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelantine capsules, solutions, emulsions or suspensions.
  • the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelantine capsules.
  • Suitable carriers for soft gelantine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelantine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • medicaments containing a compound of formula (I) or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described.
  • compositions comprising compounds of the invention:
  • Step 4 4-r(6-Chloro-3-pyridyl)methyll-l-fluoro-naphthalene-2-carboxylic acid
  • Step 1 4-Bromo- l-fluoro-N-(( 3RS,4SR)-3-hvdroxytetrahvdro-2H-pyran-4-yl)-2- naphthamide
  • Step 2 l-Fluoro-N-((3RS,4SR)-3-hvdroxytetrahvdro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-2-naphthamide
  • the mixture was cooled to room temperature, diluted with ethyl acetate and washed with water. The aqueous layer was back-extracted once with ethyl acetate. The combined organic fractions were dried over Na 2 S0 4 , filtered and concentrated. The crude product was purified by silica gel chromatography using a heptane/EtOAc gradient as eluent to obtain the title compound (240 mg, 79%) as white solid.
  • Step 1 Methanesulfonic acid tetrahvdro-pyran-4-yl ester
  • the resultant white suspension was diluted with water (250 ml) and then with aqueous solution of Na 2 S0 3 .
  • the mixture was stirred at 25°C for 10 min, then basified by addition of saturated aqueous solution of NaHC0 3 .
  • the organic layer was separated, and the aqueous layer was re-extracted with CH 2 C1 2 .
  • the combined organic layers were washed with saturated aqueous solution of NaHC0 3 (100 ml), and brine (80 ml), dried over anhydrous Na 2 S0 4 , filtered and concentrated in vacuo to afford the title compound (5 g, 70%; crude) as yellow liquid.
  • Step 6 (3S, 4R)-3-Hvdroxy-tetrahvdro-pyran-4-yl)-carbamic acid benzyl ester and ((3R, 4S)- 3-hvdroxy-tetrahydro-pyran-4-yl)-carbamic acid benzyl ester
  • examples 2 and 3 of the following table were prepared by coupling 4-((6-chloropyridin-3-yl)methyl)-l-fluoro-2-naphthoic acid (example A. l) with an amine.
  • Step 1 4-Bromo-l-fluoro-N-((lS,2S)-2-hydroxycyclohexyl)-2-naphthamide
  • More potassium trifluoro(vinyl)borate (41.7 mg, 311 ⁇ ) was added and the mixture was stirred at 160°C for 30 minutes under microwave irradiation, then diluted with water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over Na 2 S0 4 , filtered and concentrated. The crude product was purified by chromatography on Isolute ® Flash-NH 2 silica gel (from Separtis) using a heptane/EtOAc gradient to obtain the title compound (96 mg, 49%) as off white solid.
  • Step 3 l-Fluoro-4-formyl-N-((lS,2S)-2-hydroxycyclohexyl)-2-naphthamide
  • the combined organic extract was washed with water and brine, dried over Na 2 S0 4 , filtered and concentrated.
  • the crude product was purified by silica gel chromatography using a heptane/EtOAc gradient as eluent to obtain the title compound (11 mg, 56%) as white solid.
  • Step 4 4-((4-Cyano-4-(pyridin-2-yl)piperidin-l-yl)methyl)-l-fluoro-N-((lS,2S)-2-hydroxy- cyclohexyl)-2-naphthamide
EP15702398.7A 2014-01-22 2015-01-19 Fluor-naphthyl-derivate Active EP3097094B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15702398.7A EP3097094B1 (de) 2014-01-22 2015-01-19 Fluor-naphthyl-derivate

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14152124 2014-01-22
EP15702398.7A EP3097094B1 (de) 2014-01-22 2015-01-19 Fluor-naphthyl-derivate
PCT/EP2015/050830 WO2015110370A1 (en) 2014-01-22 2015-01-19 Fluoro-naphthyl derivatives

Publications (2)

Publication Number Publication Date
EP3097094A1 true EP3097094A1 (de) 2016-11-30
EP3097094B1 EP3097094B1 (de) 2020-01-15

Family

ID=49956091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15702398.7A Active EP3097094B1 (de) 2014-01-22 2015-01-19 Fluor-naphthyl-derivate

Country Status (10)

Country Link
US (1) US9708302B2 (de)
EP (1) EP3097094B1 (de)
JP (1) JP6271758B2 (de)
KR (1) KR20160098500A (de)
CN (1) CN105793259A (de)
CA (1) CA2930961A1 (de)
HK (1) HK1223919A1 (de)
MX (1) MX2016008536A (de)
RU (1) RU2016132858A (de)
WO (1) WO2015110370A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069491A (zh) 2016-02-16 2018-12-21 范德比尔特大学 毒蕈碱型乙酰胆碱受体m1的正向别构调节剂
JP6860551B2 (ja) 2016-03-11 2021-04-14 武田薬品工業株式会社 芳香環化合物
JP6629486B2 (ja) 2016-09-02 2020-01-15 スヴェン・ライフ・サイエンシズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーター
WO2018063552A1 (en) 2016-09-30 2018-04-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
JP7197472B2 (ja) * 2017-05-19 2022-12-27 武田薬品工業株式会社 スクリーニング方法
EP3700895B1 (de) * 2017-10-27 2021-09-22 Suven Life Sciences Limited Polycyclische amide als muscarin-m1-rezeptor-positive allosterische modulatoren
AU2019362468B2 (en) 2018-10-17 2022-04-21 Suven Life Sciences Limited Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507529A (ja) * 2003-09-30 2007-03-29 サイオス・インコーポレーテツド 複素環式アミドおよびスルホンアミド
WO2010090305A1 (ja) * 2009-02-09 2010-08-12 アステラス製薬株式会社 置換アシルグアニジン誘導体
ME02421B (de) * 2009-12-17 2016-09-20 Merck Sharp & Dohme Positive allosterische chinolinamid-m1-rezeptormodulatoren
WO2011149801A1 (en) * 2010-05-28 2011-12-01 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
JP6271758B2 (ja) 2018-01-31
HK1223919A1 (zh) 2017-08-11
RU2016132858A (ru) 2018-03-02
CA2930961A1 (en) 2015-07-30
EP3097094B1 (de) 2020-01-15
MX2016008536A (es) 2016-09-26
KR20160098500A (ko) 2016-08-18
CN105793259A (zh) 2016-07-20
US9708302B2 (en) 2017-07-18
JP2017501233A (ja) 2017-01-12
US20160326144A1 (en) 2016-11-10
WO2015110370A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
US9708302B2 (en) Flouro-naphthyl derivatives
US9932335B2 (en) Pyrrolopyridine or pyrazolopyridine derivatives
AU2023202086A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
CA2735764C (en) 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CA2938294C (en) Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
DK2443092T3 (en) Bicyclic and tricyclic compounds as CAT-II inhibitors
EP3049391B1 (de) Indol- und indazolderivate
US11319321B2 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
CA3163933A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3180803A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
CA3038916A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
EP4072678A1 (de) Antagonisten des muskarinischen acetylcholinrezeptors m4
KR20220079921A (ko) M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체
CA3206174A1 (en) Antagonists of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170920

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190918

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PINARD, EMMANUEL

Inventor name: GROEBKE ZBINDEN, KATRIN

Inventor name: RYCKMANS, THOMAS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015045550

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1225049

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200215

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200115

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200607

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200416

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200515

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015045550

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200119

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1225049

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

26N No opposition filed

Effective date: 20201016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200119

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20211222

Year of fee payment: 8

Ref country code: GB

Payment date: 20211228

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20211220

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20211216

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015045550

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230119

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230801

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230131